Aberrant expression of embryonic stem cell proteins such as Sox2, Oct4 and Myc has been shown in many cancer types, and the expression of these proteins in various cancer models has been found to significantly correlate with cancer stem-like (CSL) features and poor clinical outcomes [12,13,14,15,16]. This evidence concerns the gene SOX2 and cancer.